| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Devoted Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $281.91K | -- | 1 | Not available | -- | -- | $2.63B | Series F-Prime | 1/30/2026 | $317M | $16.27B | $67.50 | The Space Between, Centricus, GV, VZVC, Morgan Health, Franklin Venture Partners, VanEck, MIG Private Equity, Cox Enterprises, Premji Invest, The Private Shares Fund, NextView Ventures, Highbury, Emerson Collective, Andreessen Horowitz, BRONZE, Stardust Equity, General Catalyst, Frist Cressey Ventures, Fearless Ventures | ||||
 | Pelage | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $160.00K | -- | 1 | -- | Not available | -- | -- | $150.75M | Series B | 10/15/2025 | $120M | $314.7M | $7.23 | ARCH Venture Partners, GV, Main Street Advisors, Visionary Ventures, YK Bioventures | ||||
 | Rula | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $268.55M | Series C-1 | 2/17/2026 | $6.24M | $2.4B | $11.32 | Undisclosed Investors | ||||
 | HeartFlow | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $755.52M | Series F | 4/6/2023 | $174.86M | $546.5M | $2.85 | Bain Capital, Janus Henderson Investors, Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, Wellington Management | ||||
 | Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120.71M | Series B | 3/31/2021 | $100M | $351.77M | $35.83 | Avoro Ventures, Avoro Capital Advisors, OrbiMed, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Wellington Management, RA Capital Management, Menlo Venture | ||||
 | Cedar | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $194.00K | -- | 1 | Not available | -- | -- | $389.1M | Series D | 12/19/2022 | $255M | $3.19B | $240.52 | Tiger Global Management, Andreessen Horowitz, Thrive Capital, Concord Health Partners, Memorial Hermann Health System | ||||
 | Noom | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $500.00K | -- | 1 | Not available | -- | -- | $1.32B | Series F | 5/25/2021 | $525.46M | $3.66B | $60.34 | Silver Lake, Oak HC/FT, Temasek, Novo Holdings, Sequoia Capital, RRE, Samsung Ventures | ||||
 | Unlearn | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $135.17M | Series C | 2/8/2024 | $50M | $368.17M | $9.24 | Altimeter Capital Management, Radical Ventures, Mubadala Capital, Wittington Ventures, EPIC Ventures, Necessary Ventures, Insight Partners, 8VC, DCVC | ||||
 | Benchling | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $412.69M | Series F | 11/18/2021 | $89.62M | $6.1B | $32.70 | Franklin Templeton, Altimeter Capital, Tiger Global, Lone Pine Capital, Artisanal Ventures, Rogue Capital, Section Partners, SNR, SV Angel, Y Combinator | ||||
 | Cohere Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $171.24K | -- | 1 | Not available | -- | -- | $196.1M | Series C | 5/14/2025 | $90M | $724.92M | $13.71 | Temasek, Deerfield Management, Define Ventures, Flare Capital Partners, Longitude Capital, Polaris Partners | ||||
 | Datavant | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Freenome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.35B | Series F | 2/15/2024 | $263.96M | $2.05B | $7.40 | Roche, Andreessen Horowitz, BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates | ||||
 | Loyal | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $236.56M | Series C | 2/11/2026 | $95.46M | $614.38M | $12.26 | Age 1, Baillie Gifford | ||||
 | Cellares | Healthcare Healthcare Providers & Services | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $639.25M | Series D-1 | 5/6/2026 | $26.49M | $1.4B | $11.99 | Undisclosed Investors | ||||
 | CMR Surgical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Orca Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $541.19M | Series F | 1/9/2026 | $136.35M | $2.4B | $54.99 | Lightspeed Venture Partners | ||||
 | ADARx Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $505M | Series C | 8/9/2023 | $200M | $827.77M | $8.32 | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | ||||
 | Emerald Cloud Lab | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.12M | New Series C-1 | 7/25/2025 | $65M | $335.94M | $0.51 | Undisclosed Investors | ||||
 | Exo | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $43.94M | Series D | 5/28/2025 | $22.09M | $272.82M | $0.86 | Samsung, Sands Capital, Bold Capital, Qubit Health Capital | ||||
 | Alamar Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $248.57M | Series C | 2/26/2024 | $128.27M | $453.99M | $7.20 | Sands Capital, Sherpa Healthcare Partners, Pura Vida Investments | ||||
 | Neocis | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.37M | Series 1-D | 1/10/2024 | $109.61M | $281.57M | $8.66 | DFJ Growth, Vivo Capital, Mithril Capital Management, Norwest Venture Partners, S32, Fred Moll, Intuitive Ventures, Mirae Asset Capital, Mirae Asset Venture Investment, NVIDIA, Courtney Ventures, Florida Opportunity Fund | ||||
 | Science Corporation | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $494.02M | Series C | 3/5/2026 | $230.05M | $1.5B | $8.36 | Khosla Ventures, Lightspeed Venture Partners, Y Combinator, In-Q-Tel, Quiet Capital, Mangusta Capital, Octant Ventures, RRE Ventures | ||||
 | Lyra Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $926.79M | Series G | 1/19/2022 | $235M | $5.58B | $18.23 | Dragoneer, Salesforce Ventures, Coatue | ||||
 | Maven | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $1.45M | -- | 1 | Not available | -- | -- | $1.48B | Series F | 8/16/2024 | $125M | $1.7B | $17.77 | StepStone Group, General Catalyst, Sequoia Capital, Oak HC/FT, Icon Ventures, Dragoneer Investment Group, Lux Capital | ||||